复发性缓解型多发性硬化症患者通过口服缓解病情治疗达到无疾病活动证据-3的目标

IF 1.3 Q2 MEDICINE, GENERAL & INTERNAL
Foziah Jabbar Gossab Alshamrani, Azra Zafar, Rahmah Majed Alsawad, Zakia Yasawy, Rizwana Shahid, Saima Nazish, Erum Shariff, Nehad Mahmoud Soltan
{"title":"复发性缓解型多发性硬化症患者通过口服缓解病情治疗达到无疾病活动证据-3的目标","authors":"Foziah Jabbar Gossab Alshamrani, Azra Zafar, Rahmah Majed Alsawad, Zakia Yasawy, Rizwana Shahid, Saima Nazish, Erum Shariff, Nehad Mahmoud Soltan","doi":"10.4103/sjmms.sjmms_148_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is scant data regarding the use of oral disease-modifying treatments (oDMT) in patients with relapsing-remitting multiple sclerosis (PwRRMS) from Saudi Arabia.</p><p><strong>Objective: </strong>This study aimed to identify the response rate to oDMT in PwRRMS compared to interferon (IFN) in terms of achieving no evidence of disease activity-3 (NEDA-3).</p><p><strong>Methods: </strong>This retrospective study was conducted at a tertiary care hospital in Saudi Arabia and included all adult PwRRMS over a 2-year period who were on oDMTs or IFN for <1 year. The achievement of overall NEDA-3 and its components (namely, relapse, disability progression, and focal MRI activity) were assessed for each treatment.</p><p><strong>Results: </strong>A total of 231 patients were included for the analysis of NEDA-3 status, of which 78 (33.8%) were on oDMTs (namely, dimethyl fumarate, teriflunomide, and fingolimod). NEDA-3 status was achieved in 51.3% (OR: 1.86, 95% CI: 1.28-2.71) of patients on oDMTs and in 32% of patients on IFN (OR: 0.72, 95% CI: 0.58-0.89) (<i>P</i> < 0.001). Compared to the IFN group, the oDMT group had significantly lower rates of clinical relapse (<i>P</i> < 0.001), disability progression (<i>P</i> = 0.004), and new focal MRI activity (<i>P</i> = 0.01). Patients on dimethyl-fumarate had higher odds of achieving NEDA-3 (OR: 2.18, 95% CI = 1.09-4.34; P =0.02) compared with those on fingolimod (OR 2.15, 95% CI = 0.70-6.58; P =0.16) and teriflunomide (OR: 1.53, 95% CI = 0.81-2.91; P =0.18).</p><p><strong>Conclusion: </strong>More than half of the patients with relapsing-remitting multiple sclerosis on oral DMTs achieved NEDA-3 status in this study. Significant differences were observed in NEDA-3 status parameters and achievement between patients on oral DMTs and interferon, with the likeliness being highest among patients treated with dimethyl-fumarate.</p>","PeriodicalId":21442,"journal":{"name":"Saudi Journal of Medicine & Medical Sciences","volume":"12 4","pages":"299-305"},"PeriodicalIF":1.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556514/pdf/","citationCount":"0","resultStr":"{\"title\":\"Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing-Remitting Multiple Sclerosis.\",\"authors\":\"Foziah Jabbar Gossab Alshamrani, Azra Zafar, Rahmah Majed Alsawad, Zakia Yasawy, Rizwana Shahid, Saima Nazish, Erum Shariff, Nehad Mahmoud Soltan\",\"doi\":\"10.4103/sjmms.sjmms_148_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is scant data regarding the use of oral disease-modifying treatments (oDMT) in patients with relapsing-remitting multiple sclerosis (PwRRMS) from Saudi Arabia.</p><p><strong>Objective: </strong>This study aimed to identify the response rate to oDMT in PwRRMS compared to interferon (IFN) in terms of achieving no evidence of disease activity-3 (NEDA-3).</p><p><strong>Methods: </strong>This retrospective study was conducted at a tertiary care hospital in Saudi Arabia and included all adult PwRRMS over a 2-year period who were on oDMTs or IFN for <1 year. The achievement of overall NEDA-3 and its components (namely, relapse, disability progression, and focal MRI activity) were assessed for each treatment.</p><p><strong>Results: </strong>A total of 231 patients were included for the analysis of NEDA-3 status, of which 78 (33.8%) were on oDMTs (namely, dimethyl fumarate, teriflunomide, and fingolimod). NEDA-3 status was achieved in 51.3% (OR: 1.86, 95% CI: 1.28-2.71) of patients on oDMTs and in 32% of patients on IFN (OR: 0.72, 95% CI: 0.58-0.89) (<i>P</i> < 0.001). Compared to the IFN group, the oDMT group had significantly lower rates of clinical relapse (<i>P</i> < 0.001), disability progression (<i>P</i> = 0.004), and new focal MRI activity (<i>P</i> = 0.01). Patients on dimethyl-fumarate had higher odds of achieving NEDA-3 (OR: 2.18, 95% CI = 1.09-4.34; P =0.02) compared with those on fingolimod (OR 2.15, 95% CI = 0.70-6.58; P =0.16) and teriflunomide (OR: 1.53, 95% CI = 0.81-2.91; P =0.18).</p><p><strong>Conclusion: </strong>More than half of the patients with relapsing-remitting multiple sclerosis on oral DMTs achieved NEDA-3 status in this study. Significant differences were observed in NEDA-3 status parameters and achievement between patients on oral DMTs and interferon, with the likeliness being highest among patients treated with dimethyl-fumarate.</p>\",\"PeriodicalId\":21442,\"journal\":{\"name\":\"Saudi Journal of Medicine & Medical Sciences\",\"volume\":\"12 4\",\"pages\":\"299-305\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556514/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Saudi Journal of Medicine & Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/sjmms.sjmms_148_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Medicine & Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjmms.sjmms_148_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:关于沙特阿拉伯复发缓解型多发性硬化症(PwRRMS)患者使用口服改变病情疗法(oDMT)的数据很少:有关沙特阿拉伯复发缓解型多发性硬化症(PwRRMS)患者使用口服改变病情疗法(oDMT)的数据很少:本研究旨在确定与干扰素(IFN)相比,在达到无疾病活动证据-3(NEDA-3)方面,PwRRMS 患者对口服改变病情治疗(oDMT)的反应率:这项回顾性研究在沙特阿拉伯的一家三甲医院进行,研究对象包括所有成年 PwRRMS 患者,这些患者在两年内服用过 oDMTs 或 IFN:共有 231 名患者被纳入 NEDA-3 状态分析,其中 78 人(33.8%)使用 oDMTs(即富马酸二甲酯、特利氟胺和芬戈莫德)。51.3%的 oDMTs 患者(OR:1.86,95% CI:1.28-2.71)和 32% 的 IFN 患者(OR:0.72,95% CI:0.58-0.89)达到了 NEDA-3 状态(P < 0.001)。与 IFN 组相比,oDMT 组的临床复发率(P < 0.001)、残疾进展率(P = 0.004)和新病灶 MRI 活动率(P = 0.01)均显著降低。与芬戈莫德(OR 2.15,95% CI = 0.70-6.58;P =0.16)和特立氟胺(OR:1.53,95% CI = 0.81-2.91;P =0.18)相比,服用富马酸二甲酯的患者达到NEDA-3的几率更高(OR:2.18,95% CI = 1.09-4.34;P =0.02):结论:在本研究中,半数以上接受口服 DMTs 治疗的复发缓解型多发性硬化症患者达到了 NEDA-3 状态。口服 DMTs 和干扰素的患者在 NEDA-3 状态参数和达到 NEDA-3 状态方面存在显著差异,其中接受富马酸二甲酯治疗的患者达到 NEDA-3 状态的可能性最高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing-Remitting Multiple Sclerosis.

Background: There is scant data regarding the use of oral disease-modifying treatments (oDMT) in patients with relapsing-remitting multiple sclerosis (PwRRMS) from Saudi Arabia.

Objective: This study aimed to identify the response rate to oDMT in PwRRMS compared to interferon (IFN) in terms of achieving no evidence of disease activity-3 (NEDA-3).

Methods: This retrospective study was conducted at a tertiary care hospital in Saudi Arabia and included all adult PwRRMS over a 2-year period who were on oDMTs or IFN for <1 year. The achievement of overall NEDA-3 and its components (namely, relapse, disability progression, and focal MRI activity) were assessed for each treatment.

Results: A total of 231 patients were included for the analysis of NEDA-3 status, of which 78 (33.8%) were on oDMTs (namely, dimethyl fumarate, teriflunomide, and fingolimod). NEDA-3 status was achieved in 51.3% (OR: 1.86, 95% CI: 1.28-2.71) of patients on oDMTs and in 32% of patients on IFN (OR: 0.72, 95% CI: 0.58-0.89) (P < 0.001). Compared to the IFN group, the oDMT group had significantly lower rates of clinical relapse (P < 0.001), disability progression (P = 0.004), and new focal MRI activity (P = 0.01). Patients on dimethyl-fumarate had higher odds of achieving NEDA-3 (OR: 2.18, 95% CI = 1.09-4.34; P =0.02) compared with those on fingolimod (OR 2.15, 95% CI = 0.70-6.58; P =0.16) and teriflunomide (OR: 1.53, 95% CI = 0.81-2.91; P =0.18).

Conclusion: More than half of the patients with relapsing-remitting multiple sclerosis on oral DMTs achieved NEDA-3 status in this study. Significant differences were observed in NEDA-3 status parameters and achievement between patients on oral DMTs and interferon, with the likeliness being highest among patients treated with dimethyl-fumarate.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Saudi Journal of Medicine & Medical Sciences
Saudi Journal of Medicine & Medical Sciences MEDICINE, GENERAL & INTERNAL-
CiteScore
1.40
自引率
0.00%
发文量
52
审稿时长
15 weeks
期刊介绍: Saudi Journal of Medicine & Medical Sciences (SJMMS) is the official scientific journal of Imam Abdulrahman Bin Faisal University. It is an international peer-reviewed, general medical journal. The scope of the Journal is to publish research that will be of interest to health specialties both in academic and clinical practice. The Journal aims at disseminating high-powered research results with the objective of turning research into knowledge. It seeks to promote scholarly publishing in medicine and medical sciences. The Journal is published in print and online. The target readers of the Journal include all medical and health professionals in the health cluster such as in medicine, dentistry, nursing, applied medical sciences, clinical pharmacology, public health, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信